PGC-1α and PGC-1β thus represent viable therapeutic targets for DMD, but the mechanisms by which they reduce muscle damage in mouse models of DMD remain unclear and should be the subject of future investigations. This evidence concerns the gene PPARGC1A and Duchenne muscular dystrophy.